Adam La Caze

Adam La Caze

Auto-generated profile, based on publicly available information

Adam La Caze

The University of Queensland

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2014 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
TNThi-My-Uyen Nguyen
Thi-My-Uyen Nguyen
ACAdam La Caze
Adam La Caze
NCNeil Cottrell
Neil Cottrell

1 May 2016 in Patient Education and Counseling
Verified
Journal Article
Closed access
HFHolly Foot
Holly Foot
ACAdam La Caze
Adam La Caze
GGGina Gujral
Gina Gujral
NCNeil Cottrell
Neil Cottrell

12 September 2010 in Biology & Philosophy
Verified
Journal Article
Closed access
PDF file
ACAdam La Caze
Adam La Caze

18 August 2009 in The Journal of Medicine and Philosophy: A Forum for Bioethics and Philosophy of Medicine
Verified
Journal Article
Closed access
PDF file
ACAdam La Caze
Adam La Caze
Proponents of evidence-based medicine (EBM) provide the “hierarchy of evidence” as a criterion for judging the reliability of therapeutic decisions. EBM's hierarchy places randomized interventional studies (and systematic reviews of such studies) higher in the hierarchy than observational studies, unsystematic clinical experience, and basic science. Recent philosophical work has questioned whether EBM's special emphasis on evidence from randomized interventional studies can be justified. Following the critical literature, and in particular the work of John Worrall, I agree that many of the arguments put forward by advocates of EBM do not justify the ambitious claims that are often made on behalf of randomization. However, in contrast to the recent philosophical work, I argue that a justification for EBM's hierarchy of evidence can be provided. The hierarchy should be viewed as a hierarchy of comparative internal validity. Although this justification is defensible, the claims that EBM's hierarchy substantiates when viewed in this way are considerably more circumscribed than some claims found in the EBM literature.

30 November 2016 in BMJ Open
Verified
Journal Article
Open access
PDF file
TNThi-My-Uyen Nguyen
Thi-My-Uyen Nguyen
ACAdam La Caze
Adam La Caze
NCNeil Cottrell
Neil Cottrell
Objective To determine if a targeted and tailored intervention based on a discussion informed by validated adherence scales will improve medication adherence. Design Prospective randomised trial. Setting 2 community pharmacies in Brisbane, Australia. Methods Patients recently initiated on a cardiovascular or oral hypoglycaemic medication within the past 4–12 weeks were recruited from two community pharmacies. Participants identified as non-adherent using the Medication Adherence Questionnaire (MAQ) were randomised into the intervention or control group. The intervention group received a tailored intervention based on a discussion informed by responses to the MAQ, Beliefs about Medicines Questionnaire-Specific and Brief Illness Perception Questionnaire. Adherence was measured using the MAQ at 3 and 6 months following the intervention. Results A total of 408 patients were assessed for eligibility, from which 152 participants were enrolled into the study. 120 participants were identified as non-adherent using the MAQ and randomised to the ‘intervention’ or ‘control’ group. The mean MAQ score at baseline in the intervention and control were similar (1.58: 95% CI (1.38 to 1.78) and 1.60: 95% CI (1.43 to 1.77), respectively). There was a statistically significant improvement in adherence in the intervention group compared to control at 3 months (mean MAQ score 0.42: 95% CI (0.27 to 0.57) vs 1.58: 95% CI (1.42 to 1.75); p<0.001). The significant improvement in MAQ score in the intervention group compared to control was sustained at 6 months (0.48: 95% CI (0.31 to 0.65) vs 1.48: 95% CI (1.27 to 1.69); p<0.001). Conclusions An intervention that targeted non-adherent participants and tailored to participant-specific reasons for non-adherence was successful at improving medication adherence. Trial registration number ACTRN12613000162718; Results.

11 June 2018 in Journal of Evaluation in Clinical Practice
Verified
Journal Article
Open access
PDF file
JAJeffrey K. Aronson
Jeffrey K. Aronson
ACAdam La Caze
Adam La Caze
MKMichael Kelly
Michael Kelly
VPVeli‐Pekka Parkkinen
Veli‐Pekka Parkkinen
JWJon Williamson
Jon Williamson
The role of mechanistic evidence tends to be under‐appreciated in current evidence‐based medicine (EBM), which focusses on clinical studies, tending to restrict attention to randomized controlled studies (RCTs) when they are available. The EBM+ programme seeks to redress this imbalance, by suggesting methods for evaluating mechanistic studies alongside clinical studies. Drug approval is a problematic case for the view that mechanistic evidence should be taken into account, because RCTs are almost always available. Nevertheless, we argue that mechanistic evidence is central to all the key tasks in the drug approval process: in drug discovery and development; assessing pharmaceutical quality; devising dosage regimens; assessing efficacy, harms, external validity, and cost‐effectiveness; evaluating adherence; and extending product licences. We recommend that, when preparing for meetings in which any aspect of drug approval is to be discussed, mechanistic evidence should be systematically analysed and presented to the committee members alongside analyses of clinical studies.